Add BrightSurf on Google Email

Science News for August 28, 2021


Edoxaban may be effective treatment for atrial fibrillation after transcatheter aortic valve replacement

A large-scale international study found that edoxaban is non-inferior to warfarin for efficacy in preventing adverse events, but led to higher bleeding complications. The trial suggests that treatment with edoxaban can be valuable in managing AF patients after TAVR, especially when a lower dose of edoxaban is used.

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateAug 28, 2021